NATCOPHARM
524816Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Durga Devi Nannapaneni
Natco Pharma Ltd is a vertically integrated and research-driven pharmaceutical company headquartered in Hyderabad, India. Established in 1981, Natco specializes in the development, manufacture, and marketing of finished dosage formulations and active pharmaceutical ingredients (APIs). The company operates across both domestic and international markets, with a significant presence in highly regulated geographies such as the US, Canada, and Europe.
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Durga Devi Nannapaneni
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release & Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 regarding the investment in eGenesis, Inc.
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Investor Meet
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Conclusion of US FDS Inspection at our Visakhapatnam, Andhra Pradesh, Finished Dosage (FDF) Unit
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meet
Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Q1FY2026-27 Transcript for the Earnings call held on 14th August, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Investors meeting organised by Nuvama Wealth Management Limited and ICICI Securities Limited
Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication for the Un-Audited Financial Results for the quarter ended June 30, 2026 and declaration of Interim Dividend for the FY ending 2026-27.
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Weblink of Audio Transcript for the earnings call held on 14th August, 2026 for Q1FY2026-27
Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation for the Q1FY27
Corporate Action-Board approves Dividend
Board of Directors at their Meeting held on today i.e. 14th August, 2026 had declared Interim Dividend of Rs.1.50 (75%) for face value of Rs.2/- each
Board Meeting Outcome for Outcome Of Board Meeting
Outcome of Board Meeting
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
The Company will host an Earnings Call with Investors / Analysts on Friday, the 14th August, 2026 at 17:30 PM IST to discuss the Un-audited Financial Results of the Company for the quarter ended 30th June, 2026
Update on board meeting
Natco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Further to our earlier intimation dated August 6, 2026, pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, this is to inform you that a meeting of the Board of Directors of the Company will be held on August 14, 2026 to consider and evaluate proposals for raising funds through issuance of equity shares or other securities, including by way of a public issue, preferential issue, rights issue, private placement(s), qualified institutions placement(s) and/or any combination thereof or any other method as may be permitted in accordance with provisions of applicable laws, subject to market conditions and receipt of regulatory, statutory and other approvals as may be required
Board Meeting Intimation for Considering Un-Audited Financial Results For The Quarter Ended 30Th June, 2026 And Declare Interim Dividend, If Any
Natco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Un-audited Financial Results for the quarter ended 30th June, 2026 and declare Interim Dividend, if any for the FY 2026-27
Natco Pharma Ltd
About
Natco Pharma Ltd is a vertically integrated and research-driven pharmaceutical company headquartered in Hyderabad, India. Established in 1981, Natco specializes in the development, manufacture, and marketing of finished dosage formulations and active pharmaceutical ingredients (APIs). The company operates across both domestic and international markets, with a significant presence in highly regulated geographies such as the US, Canada, and Europe.
Natco is recognized for its strong capabilities in oncology, hepatitis C, cardiology, and niche therapeutics, focusing on complex generics, specialty pharmaceuticals, and agrochemicals.
With robust R&D infrastructure and investments, Natco has a track record of being a first-mover in the Indian generic pharmaceutical space, frequently launching generic versions of high-value drugs post-patent expiry. The company collaborates with global partners for product development, licensing, and distribution, and continues to pursue opportunities in both regulated and growth/emerging markets.
Business Model & Strategy
Natco Pharma Ltd generates revenue primarily through the development, manufacturing, and marketing of branded generics, complex generics, APIs, and specialty products. The company's business model revolves around targeting niche and high-barrier-to-entry molecules, particularly within the oncology and critical care segments. Natco has a diversified revenue base, drawing from domestic formulations, export formulations (notably in highly regulated markets), and custom synthesis for global pharmaceutical clients.
Growth strategies include expanding the product pipeline through investments in R&D, leveraging its intellectual property expertise to launch first-to-market generics, and enhancing backward integration for cost efficiency. Natco is also scaling its agrochemicals business and pursuing biosimilars and branded export opportunities, aiming for long-term sustainability across therapeutic areas and geographies.
Management Overview
11 MembersMr.VENKAIAH CHOWDARY NANNAPANENI
Executive Director-Chairperson related to Promoter-MDMr.RAJEEV NANNAPANENI
Executive Director-CEOS V V NAppaRao
Chief Financial OfficerMr.SIVARAMAKRISHNA PRASAD POTLURI
Executive DirectorMr.LINGARAO DONTHINENI
Executive DirectorMr.AGNIHOTRA DAKSHINA MURTY CHAVALI
Non-Executive - Independent DirectorMr.DRONADULA VIJAYA BHASKAR
Non-Executive - Independent DirectorMr.LAKSHMINARAYANA BOLISETTY
Non-Executive - Independent DirectorMrs.SUMA KANTIPUDI
Non-Executive - Independent DirectorMr.NITIN JAIN
Non-Executive - Independent DirectorMr.Chekuri Venkat Ramesh
Company Secretary & Compliance OfficerAwards & Recognition
5 Awards- Ranked among the top Indian pharmaceutical companies for innovation in oncology generics (Business Today Pharma Ranking 2023)
- Recipient of 'Best Innovative Product Launch' award for generic Revlimid (Lenalidomide) by ASSOCHAM, 2023
- Featured in Fortune India 500 (2024)
- Consistently recognized for strong corporate governance in NSE and BSE disclosures
- ESG Initiatives highlighted in annual report 2024, focusing on responsible manufacturing and waste management
Market Information
Company Timeline
43+ Years of Excellence | 9 Major Milestones
Company founded in Hyderabad, India
Commenced formulation manufacturing operations
Listed on the Bombay Stock Exchange (BSE)
Commissioned API manufacturing unit
Launched generic version of Bayer's Nexavar in India, setting global precedent on compulsory licensing
Entered US market with multiple ANDA launches
Launched Covifor, India's first generic Remdesivir injection for COVID-19
Expanded agrochemicals vertical; new product introductions
Significant US launch of generic Revlimid (Lenalidomide), driving international growth
The Next Evolution
Contact Information
Registered Office
Natco House, Road No 2, Banjara Hills
Tel: 040-23547532,
Fax: 040-23548243,
Email: investors@natcopharma.co.in
Website: natcopharma.co.in
Registrars
Venture Capital & Corporate Investments Pvt. Ltd
Tel: 040 - 23868023, 23818475
Email: info@vccilindia.com
Corporate Actions
33| Purpose | Ex Date | Record Date | BC Start | BC End |
|---|---|---|---|---|
Interim Dividend ₹1.50 per share | 20 Aug 2026 Thursday | 20 Aug 2026 Thursday | - | - |
Interim Dividend ₹1.50 per share | 18 Feb 2026 Wednesday | 18 Feb 2026 Wednesday | - | - |
Interim Dividend ₹1.50 per share | 20 Nov 2025 Thursday | 20 Nov 2025 Thursday | - | - |
Interim Dividend ₹2 per share | 19 Aug 2025 Tuesday | 19 Aug 2025 Tuesday | - | - |
Interim Dividend ₹1.50 per share | 18 Feb 2025 Tuesday | 18 Feb 2025 Tuesday | - | - |
Interim Dividend ₹1.50 per share | 27 Nov 2024 Wednesday | 27 Nov 2024 Wednesday | - | - |
Interim Dividend ₹3 per share | 23 Aug 2024 Friday | 23 Aug 2024 Friday | - | - |
Interim Dividend ₹1.25 per share | 26 Feb 2024 Monday | 26 Feb 2024 Monday | - | - |
Interim Dividend ₹1.25 per share | 24 Nov 2023 Friday | 24 Nov 2023 Friday | - | - |
Interim Dividend ₹7 per share | 22 Aug 2023 Tuesday | 22 Aug 2023 Tuesday | - | - |
Interim Dividend ₹1.25 per share | 21 Feb 2023 Tuesday | 21 Feb 2023 Tuesday | - | - |
Interim Dividend ₹0.75 per share | 21 Nov 2022 Monday | 22 Nov 2022 Tuesday | - | - |
Interim Dividend ₹3.50 per share | 19 Aug 2022 Friday | 22 Aug 2022 Monday | - | - |
Interim Dividend ₹2 per share | 24 Feb 2022 Thursday | 25 Feb 2022 Friday | - | - |
Interim Dividend ₹0.50 per share | 23 Nov 2021 Tuesday | 24 Nov 2021 Wednesday | - | - |
Interim Dividend ₹2 per share | 24 Aug 2021 Tuesday | 25 Aug 2021 Wednesday | - | - |
Interim Dividend ₹1 per share | 22 Feb 2021 Monday | 23 Feb 2021 Tuesday | - | - |
Interim Dividend ₹3 per share | 24 Nov 2020 Tuesday | 25 Nov 2020 Wednesday | - | - |
Interim Dividend ₹1.25 per share | 21 Aug 2020 Friday | 24 Aug 2020 Monday | - | - |
Interim Dividend ₹1 per share | 26 Jun 2020 Friday | 29 Jun 2020 Monday | - | - |
Interim Dividend ₹3.50 per share | 24 Feb 2020 Monday | 25 Feb 2020 Tuesday | - | - |
Interim Dividend ₹1 per share | 21 Nov 2019 Thursday | 22 Nov 2019 Friday | - | - |
Interim Dividend ₹1.25 per share | 22 Aug 2019 Thursday | 23 Aug 2019 Friday | - | - |
Interim Dividend ₹1.25 per share | 06 Jun 2019 Thursday | 07 Jun 2019 Friday | - | - |
Interim Dividend ₹3.50 per share | 21 Feb 2019 Thursday | 22 Feb 2019 Friday | - | - |
Interim Dividend ₹1.50 per share | 20 Aug 2018 Monday | 21 Aug 2018 Tuesday | - | - |
Interim Dividend ₹7 per share | 15 Feb 2018 Thursday | 17 Feb 2018 Saturday | - | - |
Interim Dividend ₹1.25 per share | 16 Aug 2017 Wednesday | 18 Aug 2017 Friday | - | - |
Interim Dividend ₹6 per share | 23 Feb 2017 Thursday | 27 Feb 2017 Monday | - | - |
Interim Dividend ₹0.75 per share | 19 Aug 2016 Friday | 22 Aug 2016 Monday | - | - |
Interim Dividend ₹1.25 per share | 22 Feb 2016 Monday | 23 Feb 2016 Tuesday | - | - |
Stock Split From Rs.10/- to Rs.2/- | 26 Nov 2015 Thursday | 28 Nov 2015 Saturday | - | - |
Interim Dividend ₹5 per share | 24 Feb 2015 Tuesday | 25 Feb 2015 Wednesday | - | - |
₹15,206 Cr.
₹849
₹1,227 / 789
13.29
₹514.83
1.65
₹63.89
₹2.00
0.53 %
Manage Ratio
FINANCIALS
| Annual Results | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income | - | - | - | 2,225 | 2,022 | 2,156 | 2,044 | 2,812 | 4,127 | 4,784 | 4,376 | 3,780 |
| Expenses | - | - | - | 1,400 | 1,454 | 1,576 | 1,842 | 1,950 | 2,453 | 2,493 | 2,885 | 2,675 |
| Profit | - | - | - | 642 | 458 | 442 | 170 | 715 | 1,388 | 1,883 | 1,419 | 1,145 |
| Tax | - | - | - | 182 | 111 | 137 | 32 | 147 | 285 | 408 | 119 | 91 |
| EPS | - | - | - | 35 | 25 | 24 | 9 | 39 | 77 | 105 | 79 | 11.53 |
| Ratios | - |
Cash Flow
Consolidated Figures in Rs. Crores
| Annual Balance Sheet | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | - |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | - | - | - | 4,303 | 4,588 | 4,792 | 5,109 | 5,657 | 6,906 | 8,631 | 11,074 | - |
| Equity And Liabilities | - | - | - | 4,303 | 4,588 | 4,792 | 5,109 | 5,657 | 6,906 | 8,631 | 11,074 | - |
Shareholding Pattern
Numbers in Percentages
| Quarterly SHP Announcement Date | Mar 2016 12 Apr '16 | Mar 2017 31 Mar '17 | Mar 2018 31 Mar '18 | Mar 2019 08 Apr '19 | Mar 2020 07 Apr '20 | Mar 2021 06 Apr '21 | Mar 2022 13 Apr '22 | Mar 2023 10 Apr '23 | Mar 2024 12 Apr '24 | Mar 2025 16 Apr '25 | Mar 2026 31 Mar '26 | - |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Goverments | - | - | - | - | - | - | - | - | - | - | - | - |
| Promoter And Promoter Group | - | - | - | 48.71% | 48.93% | 48.87% | 48.81% | 48.84% | 49.71% | 49.56% | - | - |
| Non Institutions | - | - | - | 22.77% | 18.83% | 18.65% | 23.10% | 23.87% | 24.45% | 27.29% | - | - |
| FII | - | - | - | - | - | - | - | 11.91% | 16.14% | 17.49% | - | - |
| DII | - | - | - | - | - | - | - | 15.38% | 9.70% | 5.65% | - | - |
| Total | - | - | - | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | - | - |
Natco Pharma Ltd
Natco Pharma Ltd
Natco Pharma Ltd is a vertically integrated and research-driven pharmaceutical company headquartered in Hyderabad, India. Established in 1981, Natco specializes in the development, manufacture, and marketing of finished dosage formulations and active pharmaceutical ingredients (APIs). The company operates across both domestic and international markets, with a significant presence in highly regulated geographies such as the US, Canada, and Europe.
Natco is recognized for its strong capabilities in oncology, hepatitis C, cardiology, and niche therapeutics, focusing on complex generics, specialty pharmaceuticals, and agrochemicals.
With robust R&D infrastructure and investments, Natco has a track record of being a first-mover in the Indian generic pharmaceutical space, frequently launching generic versions of high-value drugs post-patent expiry. The company collaborates with global partners for product development, licensing, and distribution, and continues to pursue opportunities in both regulated and growth/emerging markets.
Natco Pharma Ltd generates revenue primarily through the development, manufacturing, and marketing of branded generics, complex generics, APIs, and specialty products. The company's business model revolves around targeting niche and high-barrier-to-entry molecules, particularly within the oncology and critical care segments. Natco has a diversified revenue base, drawing from domestic formulations, export formulations (notably in highly regulated markets), and custom synthesis for global pharmaceutical clients.
Growth strategies include expanding the product pipeline through investments in R&D, leveraging its intellectual property expertise to launch first-to-market generics, and enhancing backward integration for cost efficiency. Natco is also scaling its agrochemicals business and pursuing biosimilars and branded export opportunities, aiming for long-term sustainability across therapeutic areas and geographies.
Ranked among the top Indian pharmaceutical companies for innovation in oncology generics (Business Today Pharma Ranking 2023)
Recipient of 'Best Innovative Product Launch' award for generic Revlimid (Lenalidomide) by ASSOCHAM, 2023
Featured in Fortune India 500 (2024)
Consistently recognized for strong corporate governance in NSE and BSE disclosures
ESG Initiatives highlighted in annual report 2024, focusing on responsible manufacturing and waste management
Company founded in Hyderabad, India
Commenced formulation manufacturing operations
Listed on the Bombay Stock Exchange (BSE)
Commissioned API manufacturing unit
Launched generic version of Bayer's Nexavar in India, setting global precedent on compulsory licensing
Entered US market with multiple ANDA launches
Launched Covifor, India's first generic Remdesivir injection for COVID-19
Expanded agrochemicals vertical; new product introductions
Significant US launch of generic Revlimid (Lenalidomide), driving international growth
Peer Comparison
| S.No. | Company Name | CMP (₹) | Market Cap (₹ Cr) | Div Yld (%) | NP Qtr (₹ Cr) | Qtr Profit Var (%) | Sales Qtr (₹ Cr) | Qtr Sales Var (%) | ROCE (%) | ROE (%) | Book Value (₹) | EPS TTM (₹) | TTMPE Ratio (₹) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Coming Soon
Heatmap View
Premium Feature| Company | CMP (₹) | MCap (₹ Cr) | EPS TTM (₹) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Financial Ratios
Premium Feature| Company Name | P/E (TTM) | EPS (₹) | D/E | NPM | GPM | ROE (%) | ROCE (%) | P/B | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Coming Soon